Andrew Huberman Joins Hims & Hers Board, Advises on Marketing

By Daniel Okafor

Andrew Huberman will join Hims & Hers’ board as the telehealth company serves nearly 3 million customers and prepares Peptides+, a planned section for peptide therapies.

The Stanford neuroscientist will advise Hims on science and brand marketing. He will also provide separate marketing support through the Huberman Lab podcast. This gives him a direct role in the company behind many treatments he discusses, beyond his previous outside work for fitness and sleep brands.

Business Insider said Huberman built one of the internet’s most powerful health audiences by translating science into practical advice on sleep, fitness, hormones, supplements and longevity. The Huberman Lab YouTube channel has more than 8 million subscribers, and the podcast regularly ranks among the most popular in its category. Together, they reach millions of health-conscious listeners each month.

Huberman told Business Insider: "We will never filter information differently because of a brand relationship." He said his content would keep covering benefits, risks and uncertainty, and that he would remain free to cover the category broadly. The appointment links an influential educator to a company that can sell many treatments he discusses.

Hims’ other board members include former Netflix CFO David Wells and former DoorDash CFO Kofi Amoo-Gottfried. They join Huberman as Hims expands from hair loss and erectile dysfunction into weight loss, testosterone, preventive care and peptides.

What changes when an adviser becomes a director?

Huberman first contacted CEO Andrew Dudum through a mutual friend. For the last six to eight months, they discussed the future of consumer healthcare.

Huberman said: "We have some overlapping interests," including bringing the "best healthcare practices to the broadest number of people." He added: "Joining the board allows me to do that rather than just only talk about how Hims & Hers can do that."

The board seat adds fiduciary duties and firsthand strategy involvement. Huberman now contributes scientific and marketing expertise as a director, not only as an outside adviser.

Who does Hims want to serve in the middle?

On a joint call Monday, Dudum framed the shared ambition as personalized care: "How do you empower the masses around the globe to feel better and take more agency in their life?"

Huberman sees Hims filling "this enormous gap that's existed in the middle" between traditional care, where patients struggle for time and attention, and high-end concierge care. He said "The middle 95%" should be able to access personalized care.

Hims is not alone. Business Insider cited telehealth companies Ro and Midi, longevity clinics, testing startups and consumer-health brands seeking mainstream markets for once-niche services.

Hims enters the market with nearly 3 million customers and its own pharmacy and manufacturing infrastructure. Huberman adds an audience reaching millions and lends his name to the company’s expanding menu of care.

Why do peptides raise the stakes?

The appointment carries added sensitivity because Hims is pushing into optimization, including testosterone and peptides. Peptides have moved from niche biohacking obsession to a mainstream topic in recent months.

Business Insider identified Huberman as a prominent mainstream voice on injectable peptides. Dudum has been building Hims to sell them.

Hims’ peptide plans predate the board appointment and an HHS move temporarily making some of the buzziest peptides available by prescription.

Hims signed for a California peptide facility at the end of 2024 and announced the acquisition in February 2025. By May, Dudum told investors he followed peptide innovation "deeply," citing potential uses in pain management, recovery and "generalized longevity."

In recent weeks, Hims previewed Peptides+, a website section for various peptides once regulatory approval permits, including BPC-157, along with wellness therapies such as NAD+ and vitamin B12.

Huberman said he did not want to encourage broad use among people who did not need peptides. "I don't know if somebody without an injury needs BPC and TB-500," he said.

He called Hims’ plans to control peptide manufacturing from start to finish a major reason for joining. He also cited its commitment to explaining what peptides can and cannot do. "You have to be a channel, not a dam to this kind of information," he said.

Dudum said the emerging world of personalized health and longevity "needs to be navigated extremely carefully and very cautiously."

Can Huberman preserve editorial independence?

Huberman repeated that his coverage would address benefits, risks and uncertainty. Hims had also encouraged him to continue education independent of "any kind of product or platform."

He did not specify how each podcast episode, social post or short clip would disclose his board seat and separate marketing relationship with Hims. His media company, Scicomm Media, will run podcast ads for Hims and receive payment.

Huberman said Hims could offer a more rigorous route through abundant wellness information. "It really turns people into scientists of themselves," he said.

The unresolved issue is whether that rigor survives when one of the voices guiding consumers also sits on the seller’s board and helps market its services. The next test arrives as Hims prepares Peptides+ and Huberman continues covering the same category from the board.